THERAVANCE BIOPHARMA ®, THERAVANCE ® and the Cross/Star logo are registered trademarks ... of $25 million will be triggered if Royalty Pharma (RP) receives $240 million or more in royalty payments ...

Concluded targeted enrollment of Phase 3 INDIGO trial evaluating obexelimab for the treatment of Immunoglobulin G4-Related ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm finds it “frustrating” that despite the favorable Zantac settlement, robust ...

GSK’s Trelegy, a treatment for chronic obstructive pulmonary disease (COPD), aimed to address a gap in the market with its ...

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

DelveInsight's Glucose Syrup Market Insights report provides the current and forecast market analysis, individual leading ...

GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...